← All compounds · evidence tier first, by design
| Use | E1 | E2 | E3 | E4 | E5 | E6 | E7 | E8 |
|---|---|---|---|---|---|---|---|---|
| E3 Barth syndrome (muscle strength, exercise capacity, fatigue) | E3 | |||||||
| E3 Primary mitochondrial myopathy | E3 | |||||||
| E3 Dry age-related macular degeneration with geographic atrophy | E3 | |||||||
| E3 Age-related decline in muscle function and exercise capacity (anti-ageing claims) | E3 |
Elamipretide
Synthetic tetrapeptide D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2 (FDA label: D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide); contains a D-amino acid and a non-standard dimethyltyrosine, so no one-letter sequence is given.
Non-standard residues or modifications: no plain one-letter sequence
Also: Bendavia · Codes: SS-31, MTP-131 · Brands: Forzinity
A synthetic four-residue peptide that binds cardiolipin, a lipid of the inner mitochondrial membrane. The US FDA granted it accelerated approval in September 2025 (brand Forzinity) for muscle strength in Barth syndrome, a rare inherited mitochondrial disease, on the basis of an intermediate endpoint, with a confirmatory trial required. It has also been tested in primary mitochondrial myopathy, dry macular degeneration and heart failure. Under the research name SS-31 it is also sold outside medical channels with anti-ageing and mitochondrial-health claims.
- US A approved
- EU ? not verified
- UK ? not verified
- CA ? not verified
- AU ? not verified
- JP ? not verified
- CN ? not verified
01Regulatory status, by jurisdiction
| Jurisdiction | Status | Detail and primary source |
|---|---|---|
| US | Approved | On 19 September 2025 FDA granted accelerated approval to Forzinity (elamipretide) injection, Stealth BioTherapeutics, NDA 215244, for Barth syndrome. Approval is based on knee extensor muscle strength, an intermediate endpoint; FDA requires a randomised, double-blind, placebo-controlled confirmatory trial, and continued approval may be contingent on it.“Today, the U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome”FDA Grants Accelerated Approval to First Treatment for Barth Syndrome (FDA News Release, September 19, 2025) · retrieved 2026-10-10 |
| EU UK CA AU JP CN | Not yet verified from a primary source. No status is shown rather than an unsourced one. | |
Sport (WADA): Not prohibited. Not named on the Prohibited List. As an approved medicine it also falls outside class S0, which covers only substances without current regulatory approval: “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use” WADA source
02What the human evidence shows
Barth syndrome (muscle strength, exercise capacity, fatigue)
The only controlled evidence is TAZPOWER, a randomised, double-blind, placebo-controlled crossover trial in 12 males with Barth syndrome. In the randomised part neither primary endpoint (six-minute walk distance and a Barth symptom score) was met. In the open-label extension, without a concurrent control group, walk distance, symptom scores and knee extensor strength improved from baseline. FDA's accelerated approval rests on knee extensor strength, an intermediate endpoint, and FDA requires a randomised placebo-controlled confirmatory trial (registered as 4TAZPower).
- [1] Neither primary endpoint was met in the randomised crossover phase in 12 patients; improvements from baseline were reported in the uncontrolled open-label extension
Registered-study counts: ClinicalTrials.gov intervention search “elamipretide Barth”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Primary mitochondrial myopathy
n/c: not counted here; see the cited review.
Two small randomised trials (MMPOWER, 36 participants, five days of intravenous dosing; MMPOWER-2, 30 participants, four-week crossover) did not meet their primary walk-test endpoint at conventional significance, though some secondary and patient-reported measures favoured elamipretide. The larger phase 3 trial (MMPOWER-3, 218 participants, 24 weeks) did not meet either primary endpoint; the between-group difference in walk distance was close to zero. The randomised evidence is therefore conflicting at best, and the largest trial was negative.
- [2] No difference from placebo in six-minute walk distance or fatigue score at 24 weeks in 218 participants with primary mitochondrial myopathy
- [3] Primary walk-test endpoint not statistically significant over four weeks in 30 participants; patient-reported fatigue scores favoured elamipretide
- [4] Highest intravenous dose group walked farther than placebo after five days in 36 participants (unadjusted comparison not significant)
Registered-study counts: ClinicalTrials.gov intervention search “elamipretide mitochondrial myopathy”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Dry age-related macular degeneration with geographic atrophy
n/c: not counted here; see the cited review.
ReCLAIM-2, a randomised, double-masked, placebo-controlled phase 2 trial in 176 patients treated for 48 weeks, did not meet either primary endpoint (low-luminance visual acuity and growth of the atrophic area). Differences favouring elamipretide were reported on ellipsoid-zone imaging measures with nominal p-values. A phase 3 trial (ReNEW) is registered; no results were identified.
- [5] Primary visual-acuity and atrophy-growth endpoints not met in 176 patients; nominal differences on retinal imaging measures
Registered-study counts: ClinicalTrials.gov intervention search “elamipretide macular degeneration”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Age-related decline in muscle function and exercise capacity (anti-ageing claims)
This is the main gray-market claim for SS-31. In aged female mice, eight weeks of treatment increased in-vivo mitochondrial ATP production and treadmill endurance. The one human randomised trial identified gave a single intravenous infusion to 39 healthy adults aged 60 to 85: a measure of maximal mitochondrial ATP production in a hand muscle rose briefly after infusion, was not different at day 7, and fatigue resistance did not change. No human trial has tested longer-term use for ageing, frailty or exercise performance.
- [6] Single infusion transiently raised a spectroscopic measure of mitochondrial capacity in older adults; no effect on muscle fatigue resistance
- [7] Eight weeks of SS-31 increased treadmill endurance and muscle mitochondrial ATP production in aged female mice
Registered-study counts: ClinicalTrials.gov intervention search “elamipretide”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Key registered trials
| NCT | Title (as registered) | Phase | Status |
|---|---|---|---|
| NCT03098797 | A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome | 2/3 | Completed |
| NCT07531251 | Clinical Trial in Patients With Barth Syndrome- 4TAZPower | 4 | Recruiting |
| NCT03323749 | A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension | 3 | Terminated |
| NCT03891875 | ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA | 2 | Completed |
03Safety signals
- Injection site reactions [3]
Injection site reactions were the most common adverse event in controlled trials; in the MMPOWER-2 crossover trial they were reported in 80% of participants during elamipretide treatment, mostly mild. - Hypersensitivity reactions [8]
The US label warns that hypersensitivity reactions, including serious allergic reactions requiring emergency medical intervention, have been reported, and lists serious hypersensitivity as a contraindication. - Eosinophilia [8]
The US label reports frequent increases in blood eosinophil counts in studies lasting 30 days or more, peaking around 90 days; these were not associated with clinical manifestations.
04What is unknown
- Whether the knee-strength improvement underlying the US accelerated approval translates into functional benefit in Barth syndrome; the required confirmatory randomised trial has not reported
- The approved-use evidence base is 12 patients; long-term safety beyond the small Barth syndrome extension cohort and a few hundred trial participants elsewhere is not characterised
- No human trial has tested repeated use in healthy older adults for ageing, frailty or exercise capacity; the human ageing evidence is a single-infusion biomarker study
- Not named on the 2026 WADA Prohibited List; since the 2025 US approval it falls outside S0, which covers only substances with no current approval anywhere
- Regulatory status outside the US was not verified from regulator sources for this record
05Product quality
No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.
06Citations
- A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism (2021). doi:10.1038/s41436-020-01006-8
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (2023). PMID 37268435
- A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy (2020). doi:10.1002/jcsm.12559
- Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (2018). doi:10.1212/WNL.0000000000005255
- ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation (2024). doi:10.1016/j.xops.2024.100628
- In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial (2021). doi:10.1371/journal.pone.0253849
- Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice (2019). doi:10.1016/j.freeradbiomed.2018.12.031
- FORZINITY (elamipretide) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf
Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.
07Mechanism
Elamipretide is a cell-permeable peptide that concentrates at the inner mitochondrial membrane and binds cardiolipin; in aged mice it increased in-vivo mitochondrial ATP production in skeletal muscle.
Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.
Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.